Targeting wide-range oncogenic transformation via PU24FCI, a specific inhibitor of tumor Hsp90 Academic Article uri icon

Overview

MeSH Major

  • Adenine
  • Anisoles
  • Antineoplastic Agents
  • Cell Transformation, Neoplastic
  • HSP90 Heat-Shock Proteins
  • Neoplasms

abstract

  • Agents that inhibit Hsp90 function hold significant promise in cancer therapy. Here we present PU24FCl, a representative of the first class of designed Hsp90 inhibitors. By specifically and potently inhibiting tumor Hsp90, PU24FCl exhibits wide-ranging anti-cancer activities that occur at similar doses in all tested tumor types. Normal cells are 10- to 50-fold more resistant to these effects. Its Hsp90 inhibition results in multiple anti-tumor-specific effects, such as degradation of Hsp90-client proteins involved in cell growth, survival, and specific transformation, inhibition of cancer cell growth, delay of cell cycle progression, induction of morphological and functional changes, and apoptosis. In concordance with its higher affinity for tumor Hsp90, in vivo PU24FCl accumulates in tumors while being rapidly cleared from normal tissue. Concentrations achieved in vivo in tumors lead to single-agent anti-tumor activity at non-toxic doses.

publication date

  • June 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.chembiol.2004.04.008

PubMed ID

  • 15217612

Additional Document Info

start page

  • 787

end page

  • 97

volume

  • 11

number

  • 6